{"id":"tmx-smx-bactrim-r","safety":{"commonSideEffects":[{"rate":"3-6","effect":"Rash"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Vomiting"},{"rate":"2-4","effect":"Diarrhea"},{"rate":"0.1-0.5","effect":"Stevens-Johnson syndrome"},{"rate":"0.5-1","effect":"Hepatotoxicity"},{"rate":"1-2","effect":"Hematologic abnormalities (thrombocytopenia, leukopenia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trimethoprim inhibits bacterial dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for nucleotide synthesis. Sulfamethoxazole inhibits dihydropteroate synthase, blocking the synthesis of dihydrofolate from para-aminobenzoic acid. Together, these agents provide synergistic bactericidal activity against a broad spectrum of gram-positive and gram-negative bacteria.","oneSentence":"TMX-SMX (trimethoprim-sulfamethoxazole) is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:05.378Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urinary tract infections"},{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"},{"name":"Bacterial infections (respiratory, gastrointestinal, skin and soft tissue)"},{"name":"Toxoplasmosis prophylaxis in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT00367081","phase":"PHASE4","title":"Treatment of Cerebral Toxoplasmosis in HIV/AIDS","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2003-05","conditions":"Toxoplasmic Encephalitis, AIDS","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TMX-SMX (Bactrim(R))","genericName":"TMX-SMX (Bactrim(R))","companyName":"Department of Medical Services Ministry of Public Health of Thailand","companyId":"department-of-medical-services-ministry-of-public-health-of-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TMX-SMX (trimethoprim-sulfamethoxazole) is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase. Used for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Bacterial infections (respiratory, gastrointestinal, skin and soft tissue).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}